EPR: Evidence and fallacy.

[1]  Seiji Miura,et al.  Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[2]  N. Rapoport,et al.  Effect of ultrasound on the permeability of vascular wall to nano-emulsion droplets. , 2013, Ultrasound in medicine & biology.

[3]  J. Milam,et al.  Posttraumatic growth, quality of life, and treatment symptoms among cancer chemotherapy outpatients. , 2013, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[4]  E. Azzopardi,et al.  The enhanced permeability retention effect: a new paradigm for drug targeting in infection. , 2013, The Journal of antimicrobial chemotherapy.

[5]  N. Takahashi,et al.  Dense Accumulation of Lipiodol Emulsion in Hepatocellular Carcinoma Nodule during Selective Balloon-occluded Transarterial Chemoembolization: Measurement of Balloon-occluded Arterial Stump Pressure , 2013, CardioVascular and Interventional Radiology.

[6]  Alexander T Florence,et al.  "Targeting" nanoparticles: the constraints of physical laws and physical barriers. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[7]  Joseph W. Nichols,et al.  Odyssey of a cancer nanoparticle: from injection site to site of action. , 2012, Nano today.

[8]  Francesco M Veronese,et al.  State of the art in PEGylation: the great versatility achieved after forty years of research. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[9]  Y. Barenholz.  Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[10]  B. Shoichet,et al.  Colloidal Aggregation Affects the Efficacy of Anticancer Drugs in Cell Culture , 2012, ACS chemical biology.

[11]  R. Jain,et al.  Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner , 2012, Nature nanotechnology.

[12]  R. Sanson-Fisher,et al.  Cancer Treatment Survey (CaTS): development and validation of a new instrument to measure patients' preparation for chemotherapy and radiotherapy , 2012, Psycho-oncology.

[13]  Mauro Ferrari,et al.  Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[14]  Yechezkel Barenholz,et al.  Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome. , 2012, Nanomedicine : nanotechnology, biology, and medicine.

[15]  Rakesh K Jain,et al.  Delivery of molecular and cellular medicine to solid tumors. , 1997, Advanced drug delivery reviews.

[16]  A. Hasenburg,et al.  Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial) , 2011, BMC Cancer.

[17]  H. Shim,et al.  Molecular portraits of intratumoral heterogeneity in human ovarian cancer. , 2011, Cancer letters.

[18]  R. Gatenby,et al.  A multiscale model of the bone marrow and hematopoiesis. , 2011, Mathematical biosciences and engineering : MBE.

[19]  Jun Fang,et al.  The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.

[20]  Dai Fukumura,et al.  Scaling rules for diffusive drug delivery in tumor and normal tissues , 2011, Proceedings of the National Academy of Sciences.

[21]  R. Jain,et al.  Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.

[22]  Ick Chan Kwon,et al.  Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. , 2010, Journal of Controlled Release.

[23]  Ming-Zher Poh,et al.  Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions. , 2010, Biophysical journal.

[24]  Samir Mitragotri,et al.  Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. , 2010, Current pharmaceutical design.

[25]  Z. Werb,et al.  Tumors as organs: complex tissues that interface with the entire organism. , 2010, Developmental cell.

[26]  Christine Allen,et al.  The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. , 2010, Molecular pharmaceutics.

[27]  Hiroshi Maeda,et al.  Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. , 2010, Bioconjugate chemistry.

[28]  Dai Fukumura,et al.  Tumor Microvasculature and Microenvironment: Novel Insights Through Intravital Imaging in Pre‐Clinical Models , 2010, Microcirculation.

[29]  C. Allen,et al.  Block copolymer micelles for delivery of cancer therapy: transport at the whole body, tissue and cellular levels. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[30]  Robert K Prud'homme,et al.  Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy , 2009, Expert opinion on drug delivery.

[31]  A. Bao,et al.  [(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. , 2009, Nuclear medicine and biology.

[32]  E. Miele,et al.  Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer , 2009, International journal of nanomedicine.

[33]  J. Ajani,et al.  Docetaxel-related side effects and their management. , 2009, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

[34]  Ick Chan Kwon,et al.  Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[35]  A. Ullrich,et al.  Paul Ehrlich's magic bullet concept: 100 years of progress , 2008, Nature Reviews Cancer.

[36]  Sung-Bae Kim,et al.  Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer , 2008, Breast Cancer Research and Treatment.

[37]  P. Sonneveld,et al.  Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  D. Mutch,et al.  Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  S. Pun,et al.  Increased nanoparticle penetration in collagenase-treated multicellular spheroids , 2007, International journal of nanomedicine.

[40]  K. Tanabe,et al.  Cancer immunoediting from immune surveillance to immune escape , 2007, Immunology.

[41]  G. Melillo.  Targeting hypoxia cell signaling for cancer therapy , 2007, Cancer and Metastasis Reviews.

[42]  Khaled Greish,et al.  Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines , 2007, Journal of drug targeting.

[43]  M. Kanematsu,et al.  Lipiodol retention and massive necrosis after lipiodol-chemoembolization of hepatocellular carcinoma: Correlation between computed tomography and histopathology , 1993, CardioVascular and Interventional Radiology.

[44]  J. Carlsson,et al.  Penetration of substances into tumor tissue—A methodological study on cellular spheroids , 1981, In Vitro.

[45]  S. Tosatti,et al.  Biomedical interfaces: titanium surface technology for implants and cell carriers. , 2006, Nanomedicine.

[46]  Volker Wagner,et al.  The emerging nanomedicine landscape , 2006, Nature Biotechnology.

[47]  M J Hawkins,et al.  Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  D. Groothuis,et al.  Therapeutic implications of tumor interstitial fluid pressure in subcutaneous RG-2 tumors. , 2006, Neuro-oncology.

[49]  M. Dewhirst,et al.  Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. , 2006, Journal of the National Cancer Institute.

[50]  R. Rifkin,et al.  Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma , 2006, Cancer.

[51]  David Schrama,et al.  Antibody targeted drugs as cancer therapeutics , 2006, Nature Reviews Drug Discovery.

[52]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[53]  Michael Hawkins,et al.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Michael Levi.  Classic Kaposi's sarcoma. , 2005, Journal of the American Podiatric Medical Association.

[55]  Y. Bae,et al.  Doxorubicin loaded pH-sensitive micelle targeting acidic extracellular pH of human ovarian A2780 tumor in mice , 2005, Journal of drug targeting.

[56]  C. de Lange Davies,et al.  Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx™) in human osteosarcoma xenografts , 2005, British Journal of Cancer.

[57]  M. Flessner,et al.  Resistance of Tumor Interstitial Pressure to the Penetration of Intraperitoneally Delivered Antibodies into Metastatic Ovarian Tumors , 2005, Clinical Cancer Research.

[58]  E. Rofstad,et al.  Comparison of tumor blood perfusion assessed by dynamic contrast‐enhanced MRI with tumor blood supply assessed by invasive imaging , 2005, Journal of magnetic resonance imaging : JMRI.

[59]  Chiming Wei,et al.  The pathway to commercialization for nanomedicine. , 2005, Nanomedicine : nanotechnology, biology, and medicine.

[60]  Y. Hiraku,et al.  Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. , 2005, Life sciences.

[61]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[62]  C. Shapiro,et al.  Cardiac safety of liposomal anthracyclines. , 2004, Seminars in oncology.

[63]  D. Alberts,et al.  Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. , 2004, Seminars in oncology.

[64]  S. Chan,et al.  Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[65]  C. Davies,et al.  Collagenase Increases the Transcapillary Pressure Gradient and Improves the Uptake and Distribution of Monoclonal Antibodies in Human Osteosarcoma Xenografts , 2004, Cancer Research.

[66]  Jay W. Shin,et al.  Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma–associated herpesvirus , 2004, Nature Genetics.

[67]  A. Santoro,et al.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  A. Bao,et al.  Direct 99mTc Labeling of Pegylated Liposomal Doxorubicin (Doxil) for Pharmacokinetic and Non-Invasive Imaging Studies , 2004, Journal of Pharmacology and Experimental Therapeutics.

[69]  Yechezkel Barenholz,et al.  Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs , 1993, Pharmaceutical Research.

[70]  Rakesh K. Jain,et al.  Vascular and interstitial barriers to delivery of therapeutic agents in tumors , 1990, Cancer and Metastasis Reviews.

[71]  H. Maeda,et al.  A pharmacokinetic simulation model for chemotherapy of brain tumor with an antitumor protein antibiotic, neocarzinostatin , 1981, Cancer Chemotherapy and Pharmacology.

[72]  J. Kopeček,et al.  The Influence of Cytotoxicity of Macromolecules and of VEGF Gene Modulated Vascular Permeability on the Enhanced Permeability and Retention Effect in Resistant Solid Tumors , 2004, Pharmaceutical Research.

[73]  R. Jain,et al.  Solid stress generated by spheroid growth estimated using a linear poroelasticity model. , 2003, Microvascular research.

[74]  J. Verweij,et al.  Pharmacological Effects of Formulation Vehicles , 2003, Clinical pharmacokinetics.

[75]  Rakesh K Jain,et al.  Molecular regulation of vessel maturation , 2003, Nature Medicine.

[76]  Hans-Peter Lipp,et al.  Toxicity of platinum compounds , 2003, Expert opinion on pharmacotherapy.

[77]  Jun Fang,et al.  Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. , 2003, International immunopharmacology.

[78]  J. M. Harris,et al.  Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.

[79]  Yechezkel Barenholz,et al.  Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.

[80]  D. McDonald,et al.  Significance of blood vessel leakiness in cancer. , 2002, Cancer research.

[81]  Saroja Ramanujan,et al.  Diffusion and convection in collagen gels: implications for transport in the tumor interstitium. , 2002, Biophysical journal.

[82]  Terry L. Smith,et al.  Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  D. Keefe,et al.  Anthracycline-induced cardiomyopathy. , 2001, Seminars in oncology.

[84]  D Guthrie,et al.  Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  H. Maeda,et al.  Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[86]  H. S. Oh,et al.  In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[87]  R. B. Campbell,et al.  Role of tumor–host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[88]  R. Vile,et al.  Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[89]  H. Maeda,et al.  SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. , 1991, Advanced drug delivery reviews.

[90]  M. Bally,et al.  A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free Form , 2001, Drug safety.

[91]  R K Jain,et al.  Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[92]  S. Weinbaum,et al.  Starling forces that oppose filtration after tissue oncotic pressure is increased. , 2000, American journal of physiology. Heart and circulatory physiology.

[93]  R. Jain,et al.  Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. , 2000, Cancer research.

[94]  M. Dewhirst,et al.  Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. , 2000, Cancer research.

[95]  L. Guillou,et al.  Benign lymphangioendothelioma (acquired progressive lymphangioma): a lesion not to be confused with well-differentiated angiosarcoma and patch stage Kaposi's sarcoma: clinicopathologic analysis of a series. , 2000, The American journal of surgical pathology.

[96]  S. Groshen,et al.  Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[97]  R K Jain,et al.  Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.

[98]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[99]  K. Maruyama,et al.  Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice. , 1999, International journal of pharmaceutics.

[100]  G. Yancopoulos,et al.  New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF , 1999, Oncogene.

[101]  R. Gillies,et al.  Causes and effects of heterogeneous perfusion in tumors. , 1999, Neoplasia.

[102]  D. Tzemach,et al.  Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes , 1999, Cancer.

[103]  J Verweij,et al.  Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. , 1999, Cancer research.

[104]  M. Newman,et al.  Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs , 1999, Human & experimental toxicology.

[105]  D. Devine,et al.  Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)-lipids. , 1998, Archives of biochemistry and biophysics.

[106]  J. Ross,et al.  The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, Stem cells.

[107]  J. Pignon,et al.  Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. , 1998, Journal of hepatology.

[108]  M A Fischl,et al.  Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[110]  S. Stewart,et al.  Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  D. Tzemach,et al.  Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals , 1997 .

[112]  R. K. Jain,et al.  Interstitial fluid pressure in intracranial tumours in patients and in rodents. , 1997, British Journal of Cancer.

[113]  R K Jain,et al.  Tumor angiogenesis and interstitial hypertension. , 1996, Cancer research.

[114]  Dayan Ad.  Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl). , 1996 .

[115]  J. V. Von Roenn,et al.  Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  P. Volberding,et al.  Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's Sarcoma , 1996, Journal of clinical pharmacology.

[117]  R. Skalak,et al.  Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. , 1995, Cancer research.

[118]  A. Gabizon,et al.  Liposome circulation time and tumor targeting: implications for cancer chemotherapy , 1995 .

[119]  M. Boyd,et al.  Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen , 1995 .

[120]  Y. Ichinose,et al.  The correlation between tumor size and lymphatic vessel invasion in resected peripheral stage I non-small-cell lung cancer. A potential risk of limited resection. , 1994, The Journal of thoracic and cardiovascular surgery.

[121]  R. Jain,et al.  Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. , 1994, Cancer research.

[122]  D. Ribatti,et al.  Bone marrow angiogenesis and progression in multiple myeloma , 1994, British journal of haematology.

[123]  Y. Barenholz,et al.  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.

[124]  Teruo Okano,et al.  Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly(ethylene oxide-aspartate) block copolymer-Adriamycin conjugates , 1994 .

[125]  M. Newman,et al.  Pharmacokinetics, Biodistribution and Therapeutic Efficacy of Doxorubicin Encapsulated in Stealth® Liposomes (Doxil®) , 1994 .

[126]  S. Horwitz.  Taxol (paclitaxel): mechanisms of action. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[127]  R Bicknell,et al.  Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. , 1993, Cancer research.

[128]  M. Winterhalter,et al.  Liposome stability and formation: experimental parameters and theories on the size distribution. , 1993, Chemistry and physics of lipids.

[129]  E. Eisenhauer,et al.  Clinical toxicities encountered with paclitaxel (Taxol). , 1993, Seminars in oncology.

[130]  M. Gottesman.  How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. , 1993, Cancer research.

[131]  Nandini V. Katre,et al.  The conjugation of proteins with polyethylene glycol and other polymers: Altering properties of proteins to enhance their therapeutic potential , 1993 .

[132]  R. Weiss.  The anthracyclines: will we ever find a better doxorubicin? , 1992, Seminars in oncology.

[133]  J. Weinstein,et al.  Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. , 1992, Cancer research.

[134]  R K Jain,et al.  Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. , 1992, Cancer research.

[135]  H. Maeda,et al.  Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. , 1992, Bioconjugate chemistry.

[136]  K Messmer,et al.  Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. , 1992, Cancer research.

[137]  A. Gabizon.  Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. , 1992, Cancer research.

[138]  T. Konno.  Targeting chemotherapy for hepatoma: arterial administration of anticancer drugs dissolved in Lipiodol. , 1992, European journal of cancer.

[139]  L. Seymour.  Passive tumor targeting of soluble macromolecules and drug conjugates. , 1992, Critical reviews in therapeutic drug carrier systems.

[140]  K. Ulbrich,et al.  Preclinical evaluation of polymer-bound doxorubicin , 1992 .

[141]  A. Gabizon,et al.  Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[142]  Harold E. Dvorak,et al.  Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels , 1991, The Journal of experimental medicine.

[143]  R. Shoemaker,et al.  Induction of multiple‐drug resistance during anti‐neoplastic chemotherapy in vitro , 1991, International journal of cancer.

[144]  T M Allen,et al.  Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. , 1991, Biochimica et biophysica acta.

[145]  H. Dvorak,et al.  Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. , 1991, Cancer cells.

[146]  R. Jain,et al.  Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. , 1991, Cancer research.

[147]  R K Jain,et al.  Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. , 1990, Cancer research.

[148]  P. Cullis,et al.  Use of liposomes as injectable-drug delivery systems. , 1989, American journal of hospital pharmacy.

[149]  A. Lunderquist,et al.  In Vivo Microscopy of the Liver after Injection of Lipiodol into the Hepatic Artery and Portal Vein in the Rat , 1989, Acta radiologica.

[150]  H. Maeda,et al.  Cytotoxicity of smancs in comparison with other anticancer agents against various cells in culture. , 1989, Anticancer research.

[151]  H. Dvorak,et al.  Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. , 1988, The American journal of pathology.

[152]  A. Gabizon,et al.  Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[153]  O. Matsui,et al.  [Mechanism of lipiodol accumulation and retention in hepatic tumors--analysis in cases of simple lipiodol injection]. , 1987, Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica.

[154]  J. Levick.  Flow through interstitium and other fibrous matrices. , 1987, Quarterly journal of experimental physiology.

[155]  M. Fukuoka,et al.  [Studies on the appropriate administration of cisplatin based on pharmacokinetics and toxicity]. , 1987, Gan to kagaku ryoho. Cancer & chemotherapy.

[156]  R K Jain,et al.  Transport of molecules in the tumor interstitium: a review. , 1987, Cancer research.

[157]  H. Maeda,et al.  Anticancer effects of arterial administration of the anticancer agent SMANCS with lipiodol on metastatic lymph nodes , 1987, Cancer.

[158]  R. Lipton,et al.  Phase I clinical and pharmacokinetic study of taxol. , 1987, Cancer research.

[159]  R. Kobayashi,et al.  Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. , 1987, The New England journal of medicine.

[160]  H. Maeda,et al.  [General mechanism of intratumor accumulation of macromolecules: advantage of macromolecular therapeutics]. , 1987, Gan to kagaku ryoho. Cancer & chemotherapy.

[161]  I. Goldberg.  Free radical mechanisms in neocarzinostatin-induced DNA damage. , 1987, Free radical biology & medicine.

[162]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[163]  Y. Deugnier,et al.  [Lipiodolized angiography in hepatocellular carcinomas. Contribution of iodine-131-labelled lipiodol]. , 1986, Journal de radiologie.

[164]  R. Jain,et al.  Microvascular permeability of normal and neoplastic tissues. , 1986, Microvascular research.

[165]  H. Maeda,et al.  [Stability of high molecular weight anticancer agent SMANCS and its transfer from oil-phase to water-phase. Comparative study with neocarzinostatin]. , 1986, The Japanese journal of antibiotics.

[166]  M. Bally,et al.  Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. , 1985, Biochimica et biophysica acta.

[167]  M. Ueda,et al.  Conjugation of poly(styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties. , 1985, Journal of medicinal chemistry.

[168]  R. Jain,et al.  Effect of hyperthermia on microvascular permeability to macromolecules in normal and tumor tissues. , 1985, International journal of microcirculation, clinical and experimental.

[169]  S. Tashiro,et al.  Selective targeting of anti‐cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium , 1984, Cancer.

[170]  S. W. O'Connor,et al.  Accessibility of circulating immunoglobulin G to the extravascular compartment of solid rat tumors. , 1984, Cancer research.

[171]  H. Maeda,et al.  Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. , 1984, Cancer research.

[172]  Toshimitsu Konno,et al.  Tailor-making of protein drugs by polymer conjugation for tumor targeting: A brief review on smancs , 1984 .

[173]  K. Hasuo,et al.  Selective effects of lipiodolized antitumor agents , 1984, Journal of surgical oncology.

[174]  M. Hashida,et al.  Macromolecule-drug conjugates in targeted cancer chemotherapy. , 1984, Critical reviews in therapeutic drug carrier systems.

[175]  R K Jain,et al.  Extravascular diffusion in normal and neoplastic tissues. , 1984, Cancer research.

[176]  S. Tashiro,et al.  Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. , 1983, European journal of cancer & clinical oncology.

[177]  T. Allen,et al.  Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats. , 1983, The Journal of pharmacology and experimental therapeutics.

[178]  Patrick Couvreur,et al.  Pharmacokinetics and Distribution of a Biodegradable Drug-carrier , 1983 .

[179]  C. Presant,et al.  Tumor-imaging potential of liposomes loaded with In-111-NTA: biodistribution in mice. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[180]  N. Kaplan,et al.  Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[181]  S. Tashiro,et al.  [Use of a lipid lymphographic agent, lipiodol, as a carrier of high molecular weight antitumor agent, smancs, for hepatocellular carcinoma]. , 1982, Gan to kagaku ryoho. Cancer & chemotherapy.

[182]  T. Tsuruo,et al.  Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. , 1982, Cancer research.

[183]  B. Sears,et al.  Experimental methods in cancer therapeutics. , 1982, Journal of pharmaceutical sciences.

[184]  H. Ringsdorf,et al.  Antitumor activity of monomeric and polymeric cyclophosphamide derivatives compared with in vitro hydrolysis. , 1980, Cancer research.

[185]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.

[186]  E. Newlands,et al.  Tissue distribution and tumour localization of 99m-technetium-labelled liposomes in cancer patients. , 1979, British Journal of Cancer.

[187]  M Intaglietta,et al.  Tissue perfusion inhomogeneity during early tumor growth in rats. , 1979, Journal of the National Cancer Institute.

[188]  M. Tattersall,et al.  Possible tumor localization of Tc-99m-labeled liposomes: effects of lipid composition, charge, and liposome size. , 1978, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[189]  J. Lown,,et al.  The mechanism of the neocarzinostatin-induced cleavage of DNA. , 1978, Biochemical and biophysical research communications.

[190]  R. Timpl,et al.  Nature of the collagenous protein in a tumor basement membrane. , 1978, European journal of biochemistry.

[191]  R. Juliano,et al.  Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin. , 1978, Biochemical pharmacology.

[192]  G. Gregoriadis,et al.  Fate of a liposome-associated agent injected into normal and tumour-bearing rodents. Attempts to improve localization in tumour tissues. , 1977, Life sciences.

[193]  F. Davis,et al.  Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. , 1977, The Journal of biological chemistry.

[194]  J. Driscoll,et al.  The use of macromolecules as carriers of antitumor drugs. , 1977, European journal of cancer.

[195]  M. Tattersall,et al.  Properties of [99mTc] technetium-labelled liposomes in normal and tumour-bearing rats. , 1977, Biochemical Society transactions.

[196]  S. Snyder,et al.  Macromolecular naloxone: a novel long-acting polymer-bound drug. , 1976, Life sciences.

[197]  P. Gullino,et al.  Bulk transfer of fluid in the interstitial compartment of mammary tumors. , 1975, Cancer research.

[198]  H. Ringsdorf.  Structure and properties of pharmacologically active polymers , 1975 .

[199]  P. Gullino,et al.  Diffusion and convection in normal and neoplastic tissues. , 1974, Cancer research.

[200]  S. Cooperband,et al.  Antitumor effects of antibody-diphtheria toxin conjugates: use of hapten-coated tumor cells as an antigenic target. , 1972, Journal of the National Cancer Institute.

[201]  B. Siegel,et al.  Effect of irradiation on tumor microvascular permeability to macromolecules , 1972, Cancer.

[202]  E. Potchen,et al.  Pathophysiologic basis of soft tissue tumor scanning , 1971 .

[203]  Mego Jl,et al.  The Uptake of Labeled Proteins by Particulate Fractions of Tumor and Normal Tissues after Injection into Mice , 1965 .

[204]  B. Sylvén,et al.  Protein content and enzymatic assays of interstitial fluid from some normal tissues and transplanted mouse tumors. , 1960, Cancer research.

[205]  J. Wolff,et al.  Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. , 1948, The New England journal of medicine.

[206]  M. Wintrobe.  Nitrogen mustard therapy. , 1948, The American journal of medicine.

[207]  L. Goodman,et al.  NITROGEN MUSTARD THERAPY: Use of Methyl-Bis(Beta-Chloroethyl)amine Hydrochloride and Tris(Beta-Chloroethyl)amine Hydrochloride for Hodgkin's Disease, Lymphosarcoma, Leukemia and Certain Allied and Miscellaneous Disorders , 1946 .

[208]  P. Ehrlich,et al.  Aus Theorie und Praxis der Chemotherapie , 1911 .